长春高新：目前有逾40种处于临床阶段或已提交新药临床试验申请（IND）的候选药物

Core Viewpoint - The company is facing scrutiny regarding its high R&D expenses compared to its limited output, raising questions about potential misallocation of resources and the effectiveness of its research strategy [1] Group 1: R&D Investment - The company's R&D expenses are reported to be over three times that of Sanofi, yet the results from these investments are less than one percent of Sanofi's [1] - The company is focusing on enhancing its core competitiveness by concentrating on traditional areas such as endocrine metabolism and women's health, as well as innovative directions related to oncology, respiratory, and immunology [1] Group 2: Product Development - The company is actively advancing its product development pipeline, with over 40 candidates currently in clinical stages or having submitted Investigational New Drug (IND) applications [1]